Clinical Trial Update: Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours [Phase 2]

View source ↗

Summary

Phase 2 results update for afatinib (BIBW 2992) in patients with relapsed or refractory solid tumors, focusing on QTcF prolongation. Results were posted in 2013…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-13